Elevation of serum copper levels in Alzheimer's disease
- PMID: 12391342
- DOI: 10.1212/wnl.59.8.1153
Elevation of serum copper levels in Alzheimer's disease
Abstract
Objective: To determine whether serum trace metals and oxidative species are related to abnormal cognition in AD.
Methods: The authors studied serum peroxides, copper, iron, transferrin, and antioxidant capacity in 79 patients with AD (mean age 74.3 years; 25 men, 54 women) and in 76 cognitively normal individuals (mean age 70.1 years; 33 men, 43 women). The relation of these oxidative and trace metals to APOE epsilon4 allele frequency, neuropsychological performance, and cerebrovascular or atrophic burden, as estimated by brain MRI and ultrasonography of cerebral vessels, was evaluated.
Results: Copper level was higher (p < 0.001) in subjects with AD than control subjects (specificity = 95%, sensitivity = 60%) with a cutoff serum level of 16 micro mol/L (1.02 mg/L). An increase of 1 micro mol/L in serum copper accounted for 80% of the risk of having AD and correlated with poor neuropsychological performance and medial temporal lobe atrophy (p < 0.03). Antioxidant capacity decreased and correlated with medial temporal lobe atrophy (p < 0.009) and with APOE epsilon4 allele (p = 0.004).
Conclusions: Copper may play a role in neurodegenerative processes in AD, and serum copper measurement may prove to be a peripheral diagnostic marker for AD.
Comment in
-
Elevation of serum copper levels in Alzheimer's disease.Neurology. 2003 May 13;60(9):1559; author 1559. doi: 10.1212/wnl.60.9.1559. Neurology. 2003. PMID: 12743263 No abstract available.
Similar articles
-
An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease.Brain Res. 2008 Jun 18;1215:183-9. doi: 10.1016/j.brainres.2008.03.066. Epub 2008 Apr 6. Brain Res. 2008. PMID: 18486114
-
Metal-score as a potential non-invasive diagnostic test for Alzheimer's disease.Curr Alzheimer Res. 2013 Feb;10(2):191-8. doi: 10.2174/1567205011310020009. Curr Alzheimer Res. 2013. PMID: 23036026
-
Copper perturbation in 2 monozygotic twins discordant for degree of cognitive impairment.Arch Neurol. 2004 May;61(5):738-43. doi: 10.1001/archneur.61.5.738. Arch Neurol. 2004. PMID: 15148152
-
Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.J Alzheimers Dis. 2016;50(4):1181-9. doi: 10.3233/JAD-150611. J Alzheimers Dis. 2016. PMID: 26836154
-
Excess of serum copper not related to ceruloplasmin in Alzheimer disease.Neurology. 2005 Mar 22;64(6):1040-6. doi: 10.1212/01.WNL.0000154531.79362.23. Neurology. 2005. PMID: 15781823
Cited by
-
Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.Drugs. 2011 Jul 9;71(10):1281-320. doi: 10.2165/11591370-000000000-00000. Drugs. 2011. PMID: 21770477 Review.
-
Implications of peptide assemblies in amyloid diseases.Chem Soc Rev. 2017 Oct 30;46(21):6492-6531. doi: 10.1039/c7cs00372b. Chem Soc Rev. 2017. PMID: 28702523 Free PMC article. Review.
-
Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease.Am J Alzheimers Dis Other Demen. 2013 Feb;28(1):54-61. doi: 10.1177/1533317512467680. Epub 2012 Dec 12. Am J Alzheimers Dis Other Demen. 2013. PMID: 23242124 Free PMC article.
-
Copper enhances amyloid-beta peptide neurotoxicity and non beta-aggregation: a series of experiments conducted upon copper-bound and copper-free amyloid-beta peptide.J Mol Neurosci. 2010 May;41(1):66-73. doi: 10.1007/s12031-009-9282-8. Epub 2009 Aug 14. J Mol Neurosci. 2010. PMID: 19685013
-
Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease.Prion. 2008 Jan-Mar;2(1):23-7. doi: 10.4161/pri.2.1.6297. Epub 2008 Jan 14. Prion. 2008. PMID: 19164917 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
